Mineralys Therapeutics Inc. has announced the successful achievement of statistical significance in its Explore-CKD Phase 2 trial, which focused on reducing systolic blood pressure and urinary albumin-to-creatinine ratio (UACR) while demonstrating a favorable safety profile. The company also continues its Explore-OSA Phase 2 trial involving participants with obstructive sleep apnea (OSA) and hypertension, with topline results anticipated in the first half of 2026. Additionally, Mineralys has presented positive results from its Launch-HTN and Advance-HTN pivotal trials at scientific meetings and published them in JAMA and NEJM. The company is preparing for a pre-NDA meeting with the FDA, scheduled for the fourth quarter of 2025, as part of its strategy to advance the development of lorundrostat for treating hypertension and related conditions.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。